D
David C. Sane
Researcher at Wake Forest University
Publications - 120
Citations - 6893
David C. Sane is an academic researcher from Wake Forest University. The author has contributed to research in topics: Heart failure & Percutaneous coronary intervention. The author has an hindex of 46, co-authored 117 publications receiving 6636 citations. Previous affiliations of David C. Sane include Wake Forest Baptist Medical Center & Center for Cell and Gene Therapy.
Papers
More filters
Journal ArticleDOI
Abnormal angiogenesis in diabetes mellitus.
TL;DR: In this review, the clinical features, molecular mechanisms, and potential therapeutic options of abnormal angiogenesis in diabetes will be reviewed.
Journal ArticleDOI
Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention Results of the GOLD (AU-Assessing Ultegra) Multicenter Study
Steven R. Steinhubl,J. David Talley,Gregory A. Braden,James E. Tcheng,Peter J. Casterella,David J. Moliterno,Frank I. Navetta,Peter B. Berger,Jeffrey J. Popma,George Dangas,Richard Gallo,David C. Sane,Jorge F Saucedo,Gang Jia,A. Michael Lincoff,Pierre Theroux,David R. Holmes,Paul S. Teirstein,Dean J. Kereiakes +18 more
TL;DR: The level of platelet function inhibition as measured by a point-of-care assay is an independent predictor for the risk of MACEs after PCI.
Journal ArticleDOI
Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome.
TL;DR: In vitro evidence suggests that MMP activity may facilitate atherosclerosis, plaque destabilization, and platelet aggregation and limited evidence from clinical studies supports a role of MMPs in the development of acute coronary syndromes.
Journal ArticleDOI
Statin Therapy May Be Associated With Lower Mortality in Patients With Diastolic Heart Failure A Preliminary Report
TL;DR: Statin therapy may be associated with improved survival in patients with HF and a normal EF and after adjustment for differences in baseline clinical variables between groups, statin therapy was associated with lower mortality.
Journal ArticleDOI
The cardiovascular effects of erythropoietin
TL;DR: Early studies in heart failure patients with anemia suggest that rHuEpo therapy is safe and effective in reducing left ventricular hypertrophy, enhancing exercise performance and increasing ejection fraction.